Citius Pharmaceuticals, Inc.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | $9.2M-23.1% | $11.9M-19.7% | $14.8M-16.1% | $17.7M+44.2% | $12.2M |
| General and administrative | $18.5M+1.6% | $18.2M+19.3% | $15.3M+30.1% | $11.8M+19.5% | $9.8M |
| Stock-based compensation – general and administrative | $10.8M-8.5% | $11.8M+78.9% | $6.6M+69.4% | $3.9M+168.5% | $1.5M |
| Total Operating Expenses | $38.5M-8.3% | $42.0M+14.3% | $36.7M+10.3% | $33.3M+41.6% | $23.5M |
| Operating Loss | -$38.5M+8.3% | -$42.0M-14.3% | -$36.7M-10.3% | -$33.3M-41.6% | -$23.5M |
| Interest income | $110K-85.5% | $758K-35.7% | $1.2M+369.1% | $251K-4.0% | $262K |
| Interest expense | -$268K | — | — | — | — |
| Gain on sale of New Jersey net operating losses | $2.4M | — | $3.6M | — | — |
| Total Other Income (Expense), Net | -$158K-105.0% | $3.1M-34.0% | $4.8M+1795.4% | $251K | — |
| Loss before Income Taxes | -$38.7M+0.4% | -$38.8M-21.5% | -$32.0M+3.3% | -$33.1M-43.4% | -$23.1M |
| Income tax expense | $1.1M+83.5% | $576K+0.0% | $576K+0.0% | $576K | — |
| Net Loss | -$39.7M-0.8% | -$39.4M-21.2% | -$32.5M+3.3% | -$33.6M-45.9% | -$23.1M |
| Net loss attributable to non-controlling interest | $2.3M+703.6% | $287K | — | — | — |
| Deemed dividend on warrant extension | -$1.0M | — | -$1.2M | — | — |
| Net Loss Applicable to Common Stockholders | -$37.4M+6.8% | -$40.2M-19.3% | -$33.7M-0.2% | -$33.6M-37.3% | -$24.5M |
| Net Loss Per Share Applicable to Common Stockholders - Basic (in Dollars per share) | -$3.38+43.4% | -$5.97-7.2% | -$5.57-2321.7% | -$0.23+0.0% | -$0.23 |
| Net Loss Per Share Applicable to Common Stockholders - Diluted (in Dollars per share) | -$3.38+43.4% | -$5.97-7.2% | -$5.57 | — | — |
| Basic (in Shares) | 11.1M+64.5% | 6.7M+11.2% | 6.1M-95.9% | 146.1M+34.5% | 108.6M |
| Diluted (in Shares) | 11.1M+64.5% | 6.7M+11.2% | 6.1M | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
No Form 4 transactions on record.
Informational purposes only, not investment advice.